Creyon Bio

Join us at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal! On Sunday, October 6, our Senior Director of Chemistry, Sankha Pattanayak, Ph.D., will present insights on understanding how sequence and chemistry collude to drive antisense oligonucleotide toxicity. Learn how Creyon is advancing the field of oligonucleotide-based medicines through innovative research and AI-driven engineering for safety first. #OTS2024 #OligonucleotideTherapeutics #PrecisionMedicine

Join our CEO, Christopher Hart, Ph.D., at Biologics by Oxford Global's Biologics US 2024 in San Diego. He'll share insights on our AI-enabled platform for engineering oligonucleotide-based medicines, showcasing how we're transforming drug discovery to engineering. Learn how our approach improves efficiency by up to 100-fold and achieves an 80-90% success rate in creating pre-clinical leads. https://lnkd.in/evs_BK5n #BiologicsUS2024 #AIinDrugDevelopment #PrecisionMedicine

Our COO & General Counsel Jason Ferrone will be at the San Diego Biotech Forum on Sept 25, discussing AI applications in pharma. He'll share how our AI-enabled platform is decoding the rules for safer, quicker OBM development and how we moved from concept to clinic in just one year. https://creyonbio.com/ #DrugDevelopment #AIinHealthcare

Creyon's COO & General Counsel Jason Ferrone will be at the San Diego Biotech Forum on Sept 25. In the panel discussion, attendees can learn how our platform is engineering drugs for safety first for both rare and common diseases. #DrugDevelopment #AIinHealthcare

Our CEO Christopher Hart is at #MedInvest2024! Learn about how our AI-enabled platform decodes rules for safer, quicker OBM development, overcoming delivery challenges with targeted aptamers to reach specific cells and tissues. Discover how our approach has recently translated into positive clinical outcomes. https://lnkd.in/dusxNE3 #AIinHealthcare #DrugDelivery?

We're excited to be presenting at #MedInvest2024! Discover how we're engineering oligonucleotide-based medicines 100x more efficiently and transforming treatments for rare and common disease by optimizing for tolerability and delivery to the right cells and tissues. Join us Sept 18-19 in NYC. https://lnkd.in/eGQwZ9Y ? #PrecisionMedicine #DrugDevelopment #DrugDelivery

Our CEO Christopher Hart has published a thought-provoking viewpoint in Nucleic Acid Insights on the future of oligonucleotide-based medicines (OBMs). In the article Chris explains that to realize the full potential of OBMs, we must embrace the interrelatedness of sequence and chemistry rather than treating them as independent factors. OBMs are fundamentally programmable drugs and modern AI/ML techniques could help resolve this challenge with purpose-built data. Read the full article to learn how we can advance the field of oligonucleotide therapeutics from one of drug discovery to drug engineering: https://lnkd.in/eGndtqGb BioInsights #OligonucleotideTherapeutics #DrugDiscovery #Biotech

We're officially welcoming Shaquille Vayda, Principal at Lux Capital, to Creyon's Board of Directors! Shaq's diverse experience spanning technology, aerospace and life sciences, with a focus on discovery and delivery platforms, synthetic biology and data infrastructure, aligns well with our innovative approach to drug engineering. https://lnkd.in/e6-X4965 #BiotechLeadership #AIinDrugDiscovery

Please welcome Serge Messerlian, Operating Partner at DCVC Bio, to Creyon’s Board of Directors! With his extensive leadership in life sciences across hematology, oncology, immunology and rare diseases, Serge brings valuable expertise to support our mission of reimagining drug development through AI-enabled engineering of oligonucleotide-based medicines. https://lnkd.in/e6-X4965 #BiotechLeadership #AIinDrugDiscovery

Exciting news! Creyon has been granted another U.S. patent for our AI/machine learning-enabled engineering of therapeutic oligonucleotides. What it covers: Our proprietary method for training machine-learned models to optimize oligonucleotide designs for desired biophysical effects and pharmacological endpoints. Why it matters: This technology allows us to create the data and the models that underlie our ability to engineer potential therapies and improve lead identification efficiency by up to 100-fold over industry peers. What's next: Accelerated development of life-changing treatments for both rare and common diseases. Read our press release to learn more about how we're revolutionizing drug development: https://lnkd.in/e64DYGBM #FutureOfMedicine #AIinHealthcare